China Shineway Pharmaceutical Group Limited (2877.HK)
HKD 9.43
(-1.26%)
HKD 9.43
(-1.26%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 4.51 Billion CNY | 14.32% |
| 2022 | 3.95 Billion CNY | 22.56% |
| 2021 | 3.22 Billion CNY | 21.38% |
| 2020 | 2.65 Billion CNY | -1.86% |
| 2019 | 2.7 Billion CNY | 5.28% |
| 2018 | 2.57 Billion CNY | 33.89% |
| 2017 | 1.91 Billion CNY | -3.7% |
| 2016 | 1.99 Billion CNY | -2.99% |
| 2015 | 2.05 Billion CNY | -7.82% |
| 2014 | 2.22 Billion CNY | 1.92% |
| 2013 | 2.18 Billion CNY | 2.57% |
| 2012 | 2.13 Billion CNY | 7.44% |
| 2011 | 1.98 Billion CNY | -2.64% |
| 2010 | 2.03 Billion CNY | 24.81% |
| 2009 | 1.63 Billion CNY | 28.08% |
| 2008 | 1.27 Billion CNY | 25.9% |
| 2007 | 1.01 Billion CNY | 20.37% |
| 2006 | 841.47 Million CNY | 1.21% |
| 2005 | 831.37 Million CNY | 18.16% |
| 2004 | 703.57 Million CNY | 16.48% |
| 2003 | 604.04 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q4 | 2.11 Billion CNY | 0.0% |
| 2023 Q2 | 2.39 Billion CNY | 0.0% |
| 2023 FY | 4.51 Billion CNY | 14.32% |
| 2022 Q4 | 2.13 Billion CNY | 0.0% |
| 2022 Q2 | 1.81 Billion CNY | 0.0% |
| 2022 FY | 3.95 Billion CNY | 22.56% |
| 2021 Q4 | 1.66 Billion CNY | 0.0% |
| 2021 FY | 3.22 Billion CNY | 21.38% |
| 2021 Q2 | 1.55 Billion CNY | 0.0% |
| 2020 FY | 2.65 Billion CNY | -1.86% |
| 2020 Q2 | 1.19 Billion CNY | 0.0% |
| 2020 Q4 | 1.46 Billion CNY | 0.0% |
| 2019 Q2 | 1.36 Billion CNY | 0.0% |
| 2019 Q4 | 1.33 Billion CNY | 0.0% |
| 2019 FY | 2.7 Billion CNY | 5.28% |
| 2018 FY | 2.57 Billion CNY | 33.89% |
| 2018 Q4 | 1.26 Billion CNY | 0.0% |
| 2018 Q2 | 1.3 Billion CNY | 0.0% |
| 2017 Q4 | 1.1 Billion CNY | 0.0% |
| 2017 FY | 1.91 Billion CNY | -3.7% |
| 2017 Q2 | 811.74 Million CNY | 0.0% |
| 2016 Q2 | 931.64 Million CNY | 0.0% |
| 2016 Q4 | 1.06 Billion CNY | 0.0% |
| 2016 FY | 1.99 Billion CNY | -2.99% |
| 2015 FY | 2.05 Billion CNY | -7.82% |
| 2015 Q2 | 1.1 Billion CNY | 0.0% |
| 2015 Q4 | 945.5 Million CNY | 0.0% |
| 2014 Q4 | 1.12 Billion CNY | 0.0% |
| 2014 Q2 | 1.09 Billion CNY | 0.0% |
| 2014 FY | 2.22 Billion CNY | 1.92% |
| 2013 Q4 | 1.12 Billion CNY | 0.0% |
| 2013 Q2 | 1.05 Billion CNY | 0.0% |
| 2013 FY | 2.18 Billion CNY | 2.57% |
| 2012 Q4 | 546.77 Million CNY | 2.57% |
| 2012 Q3 | 533.06 Million CNY | 0.0% |
| 2012 Q2 | 533.06 Million CNY | 0.0% |
| 2012 Q1 | 533.06 Million CNY | 0.0% |
| 2012 FY | 2.13 Billion CNY | 7.44% |
| 2011 Q1 | 496.13 Million CNY | 0.0% |
| 2011 Q2 | 496.13 Million CNY | 0.0% |
| 2011 Q3 | 496.13 Million CNY | 0.0% |
| 2011 Q4 | 533.06 Million CNY | 7.44% |
| 2011 FY | 1.98 Billion CNY | -2.64% |
| 2010 Q4 | 496.13 Million CNY | -2.64% |
| 2010 Q1 | 509.59 Million CNY | 0.0% |
| 2010 FY | 2.03 Billion CNY | 24.81% |
| 2010 Q3 | 509.59 Million CNY | 0.0% |
| 2010 Q2 | 509.59 Million CNY | 0.0% |
| 2009 Q3 | 408.3 Million CNY | 0.0% |
| 2009 FY | 1.63 Billion CNY | 28.08% |
| 2009 Q1 | 408.3 Million CNY | 0.0% |
| 2009 Q4 | 509.59 Million CNY | 24.81% |
| 2009 Q2 | 408.3 Million CNY | 0.0% |
| 2008 Q4 | 408.3 Million CNY | 28.08% |
| 2008 FY | 1.27 Billion CNY | 25.9% |
| 2008 Q1 | 318.79 Million CNY | 0.0% |
| 2008 Q2 | 318.79 Million CNY | 0.0% |
| 2008 Q3 | 318.79 Million CNY | 0.0% |
| 2007 Q1 | 253.22 Million CNY | 0.0% |
| 2007 FY | 1.01 Billion CNY | 20.37% |
| 2007 Q4 | 318.79 Million CNY | 25.9% |
| 2007 Q3 | 253.22 Million CNY | 0.0% |
| 2007 Q2 | 253.22 Million CNY | 0.0% |
| 2006 Q1 | 210.36 Million CNY | 0.0% |
| 2006 FY | 841.47 Million CNY | 1.21% |
| 2006 Q2 | 210.36 Million CNY | 0.0% |
| 2006 Q3 | 210.36 Million CNY | 0.0% |
| 2006 Q4 | 253.22 Million CNY | 20.37% |
| 2005 Q3 | 207.84 Million CNY | 0.0% |
| 2005 Q2 | 207.84 Million CNY | 0.0% |
| 2005 FY | 831.37 Million CNY | 18.16% |
| 2005 Q4 | 210.36 Million CNY | 1.21% |
| 2005 Q1 | 207.84 Million CNY | 0.0% |
| 2004 Q4 | 207.84 Million CNY | 18.16% |
| 2004 Q1 | 175.89 Million CNY | 0.0% |
| 2004 Q2 | 175.89 Million CNY | 0.0% |
| 2004 Q3 | 175.89 Million CNY | 0.0% |
| 2004 FY | 703.57 Million CNY | 16.48% |
| 2003 FY | 604.04 Million CNY | 0.0% |
| 2003 Q1 | 151.01 Million CNY | 0.0% |
| 2003 Q4 | 175.89 Million CNY | 16.48% |
| 2003 Q3 | 151.01 Million CNY | 0.0% |
| 2003 Q2 | 151.01 Million CNY | 0.0% |
| 2002 Q4 | 151.01 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | -1642.774% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | 57.106% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -7542.455% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | -476.176% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | -369.841% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | -328.907% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | -164.658% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | -458.213% |
| PuraPharm Corporation Limited | 406.85 Million HKD | -1010.099% |
| SSY Group Limited | 6.46 Billion HKD | 30.117% |
| JBM (Healthcare) Limited | 648.41 Million HKD | -596.551% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | -207.708% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 98.33% |